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Abstract: Periprosthetic joint infection (PJI) is a rare but devastating complication after total joint
arthroplasty. An estimated 7–12% of patients have negative cultures despite clear clinical evidence of
infection. One oft-cited reason for this occurrence is the administration of antibiotics in the weeks
prior to obtaining cultures. This article reviews the influence of antibiotics on the diagnosis of PJI.
Specifically, we examine the effect of prophylactic and therapeutic antibiotic administration on the
diagnostic accuracy of microbiological cultures as well as serum and synovial biomarkers. We also
explore the potential of molecular techniques in overcoming these limitations in patients who have
received antibiotics before specimen collection and propose areas for future research.
Keywords: knee arthroplasty; hip arthroplasty; antibiotics; infection; periprosthetic joint infection;
diagnosis; culture; aspiration; molecular; synovial fluid
1. Introduction
Periprosthetic joint infection (PJI) is a rare but devastating complication after total
joint arthroplasty (TJA). The risk of PJI following total knee arthroplasty (TKA) varies
between 0.5% and 2% [1], whereas a slightly lower risk of 1% has been observed for
total hip arthroplasty (THA). Despite the low incidence of this complication, PJI is the
most common indication for revision TKA in the United States [2] and the third most
common indication for revision THA [3]. As the population ages and the demand for
joint arthroplasty continues to grow over the next decade [4], the prevalence of PJI will
invariably increase, posing a substantial economic burden to the healthcare system [5]. It
is therefore imperative that clinicians obtain a timely and accurate diagnosis to avert the
consequences of this disastrous complication.
In addition to a thorough history and physical examination, the diagnosis of PJI
often relies on serological tests and radiographic evaluation [6]. In particular, isolating
the infecting microorganism from cultures of fluid or tissue within the joint remains the
cornerstone for diagnosis and targeted antibiotic therapy, which has been shown to increase
the chances of treatment success [7]. This also provides valuable prognostic information for
patients and guides perioperative counseling [8]. According to the recent definition of PJI
proposed by the European Bone and Joint Infection Society (EBJIS), isolation of the same
pathogen from two separate intraoperative tissue or fluid samples is diagnostic of PJI [9].
However, while multiple clinical guidelines on the appropriate surgical and laboratory
techniques to maximize culture yield have been published [10], an estimated 7–12% of
patients still have negative cultures despite clear clinical evidence of infection, such as a
draining sinus or a high synovial fluid white blood cell (WBC) count [8,11,12]. An oft-cited
reason for this occurrence is the administration of antibiotics in the weeks prior to obtaining
cultures [11], prompting the guidelines of major orthopedic associations to recommend
against this practice until the diagnosis of PJI has been reliably established [13].
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This narrative review discusses the influence of antibiotics on the diagnosis of PJI.
Specifically, we examine the effects of antibiotic administration on the diagnostic accuracy
of microbiological cultures as well as serum and synovial biomarkers. We also explore the
potential of molecular techniques in overcoming these limitations in patients who have
received antibiotics before specimen collection and propose areas for future research.
2. Premature Antimicrobial Administration in Hematogenous PJI
Hematogenous PJI, a subtype of PJI, remains a unique clinical entity as patients
suffering from this complication are often at a higher risk of premature antimicrobial
administration to treat the source of infection, prior to implant revision or even the onset
of symptoms for an infected joint. This type of PJI often manifests in the late postoperative
period after an uneventful course and is usually caused by hematogenous spread from a
distant infectious focus. The incidence of late PJIs (manifesting 2 years post-implantation or
later) is estimated at 0.07% per prosthesis-year [14], and the proportion of hematogenous PJI
is estimated at 20–35% of all PJI episodes [15]. As Staphylocccus aureus is the most common
cause of bacteremia [16] and the majority of patients with S. aureus PJI obtain this infection
via the hematogenous route [17], it is often assumed that most cases of hematogenous
PJI are caused by S. aureus. However, it is important to note that this is an erroneous
presumption, since recent studies have shown that S. aureus is only responsible for 28–41%
of such cases and Streptococcal species are also highly prevalent [15,18]. With regards to the
source of hematogenous PJI, a recent study by Rakow et al. showed that the cardiovascular
system (including native or prosthetic valve endocarditis, implantable device-associated
infections, and central or peripheral catheter-related infections) was the site of primary
infection in 68% of cases [18]. In contrast, Zeller et al. determined that the skin (15%) and
teeth (11%) were the most common portals of entry in hematogenous PJIs [15], although it
remains uncertain whether “skin” infections also encompassed infected intravenous sites,
as was done in historical studies [19]. Notwithstanding, it is important that all physicians
be familiar with the epidemiology, origins, and microbiological features of hematogenous
PJI, as this can guide treatment decisions in regards to whether early administration of
antibiotic therapy is warranted, or whether such treatment may be premature and should
be deferred till after microbiological isolation of the PJI organism is performed. These
decisions have important clinical implications on the diagnosis of PJI and may do more
harm than good in most cases. The influence of antibiotic administration on the accuracy
of various laboratory tests used in the diagnosis of PJI is outlined in the following sections.
3. Antibiotics and Culture Yield
3.1. Therapeutic Antibiotics
The gold standard for the diagnosis of PJI has traditionally been the isolation of an
organism from microbiological cultures obtained intraoperatively. However, this is not
always possible despite clinical evidence confirming the presence of PJI—a phenomenon
commonly referred to as culture-negative periprosthetic joint infections (CN-PJI) [11]. The
prevalence of CN-PJI has been noted to be as high as 40% [12,20,21]. Possible reasons for
negative cultures have been proposed, such as infection by fastidious pathogens, biofilm
encapsulation, uncommon organisms (e.g., fungi or mycobacteria) that do not replicate
on routine culture media, inadequate sampling or transportation, as well as insufficient
resuscitation in the laboratory [10,22]. Nonetheless, the most important cause of failure
to isolate an organism from intraoperative cultures is the administration of antibiotics
before obtaining samples from the infected joint [11,12,23]. Sub-therapeutic or mistargeted
antimicrobial treatment has been shown to induce a viable but non-culturable (VBNC)
physiological state in many pathogens [24–27], rendering the results of these cultures falsely
negative. This cellular state is characterized by low metabolic activity and the absence
of growth on routine bacteriological media [28]. Metabolic activity and culturability can
be restored if the appropriate nutritional stimulation is provided—this process is known
as resuscitation [29]. Unfortunately, antimicrobials that act on growing cells are often
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unable to eradicate VBNC cells, likely because their metabolic activity has decreased
to such an extent that they effectively become resistant to treatment [30]. For instance,
vancomycin was found to be effective against VBNC Enterococcus faecalis cells only when
administered at five hundred times the minimum inhibitory concentration [31]. While most
pathogens are generally unable to cause infection when in a VBNC state, these bacteria
still retain their virulence and can cause infection after being resuscitated [25]. VBNC
microorganisms have been postulated to be the cause of re-infections in patients who
initially experience remission following antimicrobial therapy, as in the case of recurrent
gastric ulceration by Helicobacter pylori or recurrent urinary tract infections by Escherichia coli.
These findings likely account for the phenomenon of CN-PJI, especially in the setting of
prior antibiotic administration. False-negative results not only preclude the selection of
targeted antimicrobial therapy and lead to lower rates of treatment success [32], but also
result in unnecessary anxiety for patients who may challenge the diagnosis of PJI due to an
inability to isolate a pathogen [12]. Furthermore, empirical treatment of CN-PJI usually
entails administering broad-spectrum or multiple antibiotics to cover the most common
microorganisms according to epidemiological surveys, which may be less effective and
increases the risk of adverse reactions or systemic toxicity. Consequently, it is imperative
that extra efforts be made to isolate the infecting organism in all cases of PJI.
Culture-negative infections have been reported in multiple fields in clinical medicine [33–36].
A recent multicenter, single-group, diagnostic study of 325 patients with severe sepsis
reported a significant difference in the proportion of positive blood cultures in patients who
had specimens taken pre- (31.4%) and post-antimicrobial (19.4%) administration, indicating
that the initiation of empirical therapy reduced the sensitivity of blood cultures [35].
In addition to its implications on culture yield, septic patients who have cultures after
initiation of antimicrobials may also have longer intensive care unit (ICU) and hospital stays,
as well as greater mortality risk [34]. Current evidence in orthopedic surgery also cautions
against the use of antibiotics in the period leading up to revision arthroplasty [11,23,37,38].
Trampuz et al. demonstrated that any administration of antibiotics in the two weeks
before obtaining intraarticular cultures adversely influenced the sensitivity of cultures
and was associated with a higher false negative rate (55% vs. 23%) [37]. In another case-
control study of 60 patients, Berbari et al. found that 53% of patients who had CN-PJI
received antimicrobial therapy within three months before the diagnosis and 23% received
the antimicrobial agent up to the time samples were taken from the infected joint [11].
Similarly, Malekzadeh et al. found that patients with CN-PJI were four times more likely to
have received antimicrobial therapy in the preceding three months before diagnosis [23].
In the same vein, Shahi et al. reported that patients with antibiotic use before aspiration
had a higher rate of CN-PJI compared to those without any antibiotic history [38]. Given
these considerations, clinical practice guidelines have recommended against preemptive
treatment before a thorough evaluation for PJI, advising clinicians to withhold antibiotic
therapy for at least two weeks before intraoperative specimen collection to improve culture
yield [13]. For the same reason, the Infectious Diseases Society of America (IDSA) clinical
practice guidelines further recommend against antibiotic therapy for at least two weeks
before joint aspiration to increase the chances of isolating the causative organism [39].
Based on the available literature, the general consensus is to discontinue antibiotic therapy
for a minimum of two weeks prior to surgical intervention or culture. However, whether
these recommendations can be applied uniformly to all suspected cases of PJI remains
unknown. In particular, several authors have proposed that an even longer period without
antimicrobial exposure may be required to culture certain fastidious organisms [37,40,41].
Future research is needed to refine the present guidelines with regards to the effect of
different antimicrobial agents on the culture yield of differing organisms, as well as to define
the optimal antibiotic-free period before obtaining samples in patients with suspected PJI.
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3.2. Prophylactic Antibiotics
It is important to make a distinction between therapeutic antibiotics (which often re-
quires a prolonged course of treatment) and prophylactic antibiotics (which often comprises
a single dose administered perioperatively [42]). While the abovementioned studies have
demonstrated that antibiotic administration prior to identifying the causative pathogen
increases the risk of false-negative cultures [23], the need to withhold pre-incision prophy-
lactic antibiotics remains a controversial issue in orthopedic surgery [43–47]. Prophylactic
antibiotics were traditionally believed to interfere with culture yields from intraopera-
tive samples, leading some investigators to advocate against their use in the context of
revision arthroplasty for suspected PJI [40,48]. Although this practice appears logical,
withholding prophylactic antibiotics may increase the risk of surgical site infection or
systemic dissemination perioperatively. Moreover, recent evidence has largely refuted
this belief [43–47]. Two randomized controlled trials also demonstrated identical rates of
positive intraoperative cultures [43] and concordant cultures [44] in patients who did or
did not receive prophylactic antibiotics before incision. Utilizing intraoperative controls,
Bedencic et al. obtained samples from the same surgical site before and after cefazolin
infusion and found no difference in the mean number of colony-forming units (CFU) per
gram of tissue between the two sets of cultures. Importantly, the tissue concentrations
of cefazolin were all higher than the minimum inhibitory concentration at the time of
obtaining the second sample [45]. More recently, a large cohort study of 425 revision TKAs
reported no difference in the number of positive cultures between non-prophylaxis and
prophylaxis groups (26% vs. 27%) [47], and the species of bacteria cultured were also
similar. Furthermore, as a trend toward a higher rate of PJI in the early postoperative
period was found in the group who did not receive antibiotic prophylaxis (6.4% vs. 1.6%),
the authors cautioned against withholding prophylactic antibiotics for patients undergoing
aseptic revision arthroplasty. Given the large body of evidence suggesting that the practice
of withholding prophylactic antibiotics to maximize culture yield may not be as critical as
previously thought, the 2018 International Consensus Meeting (ICM) recommended that
perioperative antibiotic administration for revision TJA should not be routinely withheld,
but should instead be guided by the degree of clinical suspicion for PJI and whether or not
a causative organism has been isolated before surgery [10].
4. Antibiotics and Biomarkers
Serum and synovial biomarkers are useful adjuncts in the diagnosis of PJI [6], es-
pecially in the absence of major criteria such as a communicating sinus tract or two pos-
itive cultures [49]. Biomarkers are measurable biological substances that are part of a
physiological or pathological pathways or the pharmacological response to therapeutic
interventions [50]. As with its impact on culture yield, antibiotic administration prior to ob-
taining blood or synovial fluid samples may also adversely affect the accuracy of common
biomarkers used to support the diagnosis of PJI. Shahi et al. found that a higher percentage
of biomarker values were below the Musculoskeletal Infection Society (MSIS)-determined
threshold for erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and syn-
ovial polymorphonuclear cell percentage (PMN%) in patients who received antibiotics
compared to patients who did not, indicating a higher rate of false-negatives [38], and
median biomarker values were also lower in the group with antibiotic use. Two possible
mechanisms may account for these findings. Firstly, antibiotics have been shown to display
anti-inflammatory properties by inhibiting interleukin (IL)-1 and tumor necrosis factor
(TNF) production [51], and these effects may be more pronounced in certain classes of
antibiotics including macrolides and quinolones [52,53]. Secondly, antibiotics may decrease
the inflammatory response indirectly by decreasing bacterial load and macrophage activa-
tion. This leads to an attenuation of the cytokine cascade, reduction in IL-1, TNF, and IL-6,
and decrease in inflammatory markers such as ESR and CRP [54]. As synovial fluid cell
counts and differentials fluctuate according to serum levels [55,56], this will concomitantly
cause a decline in synovial biomarkers. These mechanisms support the claim that antibi-
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otics administration in patients with suspected PJI affects the values of common serologic
and synovial biomarkers used in diagnostic criteria. Future research could be directed at
establishing new cutoffs for PJI diagnosis in patients who inadvertently receive antibiotics
before a diagnostic workup.
Newer serum and synovial fluid biomarkers play an integral role in the diagnosis of PJI
and have been incorporated into recent guidelines as minor diagnostic criteria [49]. Serum
IL-6 has been established as a valuable inflammatory marker in association with sepsis,
trauma, and major surgery. Given that IL-6 lies upstream of traditional biomarkers in the
inflammatory cascade, it is postulated to be a more rapid and sensitive blood test for the
detection of PJI [57]. Berbari et al. found that IL-6 had the highest accuracy in diagnosing
PJI when compared to ESR and CRP [58]. A growing interest in the use of IL-6 has led to
its incorporation into the latest clinical practice guidelines [13]. Notwithstanding, current
barriers to its use include the relatively high cost and technical skills required to run the
analysis. As serum IL-6 assays become more widely available for clinical use, this biomarker
could be used in combination with other routine markers like CRP, further enhancing their
diagnostic yield as shown in previous studies [59]. Synovial fluid biomarkers with a high
specificity for PJI include leukocyte esterase and human alpha-defensin. Leukocyte esterase
is an enzyme secreted by activated neutrophils following their migration to the site of
infection. Its use has gained recognition in the diagnosis of urological infections, and
more recently, PJI [60]. Leukocyte esterase tests are readily available, point-of-care tests
requiring the application of infected joint fluid onto colorimetric strips. Detection of the
enzyme is then reflected as a color change on the test strip [60]. Despite its utility, one
major limitation is that the contamination of fluid samples with blood can interfere with the
colorimetric changes of the test strip [61], although this may be overcome by centrifuging
samples prior to application. Tischler et al. showed that leukocyte esterase testing had a
high specificity and moderate sensitivity in the diagnosis of PJI [61], while Wetters et al.
reported a sensitivity of 92.9–100%, and specificity of 77.0–88.8% [62]. Alpha defensin is
another synovial fluid biomarker with high accuracy when used in the diagnostic workup
for PJI [63]. Defensins are antimicrobial peptides that act on most Gram positive and
negative bacteria, fungi, and enveloped viruses [64]. They are commonly secreted by
neutrophils as well as certain macrophage cell lines, and their synthesis is induced by
pro-inflammatory cytokines or microbiological products. While their precise antimicrobial
mechanism has yet to be fully elucidated, alpha-defensins are generally believed to cause a
disruption in pathogen membrane integrity, resulting in cell lysis [64,65]. Previous studies
have demonstrated the utility of alpha-defensin as a diagnostic tool for PJI [66]. Of note,
alpha-defensin provides consistent accuracy irrespective of the infecting organism species
or virulence [63], with studies reporting a sensitivity and specificity of over 95% for the
diagnosis of PJI [66–68]. Bingham et al. even suggested that the diagnostic accuracy of
synovial fluid alpha-defensin assays exceeded that of other available tests [66]. These
encouraging results ultimately led to its incorporation into previous diagnostic criteria
for PJI [49].
Interestingly, the effect of preoperative antibiotic administration on the sensitivity
of more recent biomarkers like alpha defensin and leukocyte esterase has been found to
be negligible. Deirmengian et al. analyzed the results from a single institution and did
not find any effect of pre-aspiration antibiotic administration on alpha-defensin levels or
sensitivity [68]. These findings were corroborated by Shahi et al. in a multicenter study of
106 PJIs, who reported that the 30 cases treated with antibiotics before diagnostic workup
had a similar median alpha-defensin level compared to the 76 untreated cases, suggesting
that alpha-defensin was more sensitive than ESR, CRP, fluid PMN%, and fluid culture
when screening for PJI in the setting of antibiotic use [69]. In another study, the same
authors found that the administration of antibiotics resulted in a decrease in the median
values and diagnostic sensitivity of the aforementioned biomarkers (serum ESR, CRP,
synovial WBC, and PMN%), but this was not observed for leukocyte esterase [70]. In
addition to the practical benefits of being point-of-care tests with immediate results, these
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findings demonstrate that synovial fluid alpha-defensin assays and leukocyte esterase
strip tests maintain their diagnostic accuracy even in the unfortunate but not uncommon
circumstance wherein antibiotics have been administered prematurely, unlike serum ESR
and CRP as well as synovial fluid WBC count and PMN%. For cases in which antibiotics
have been administered prior to diagnostic workup, current evidence suggests that synovial
alpha-defensin assays and leukocyte esterase strip tests may be used as reliable tools to
support or reject the diagnosis of PJI in conjunction with the clinical presentation and other
diagnostic criteria.
5. Current Solutions: Sonication of Implants
It is possible that newer techniques for microbiological identification such as sonication
fluid cultures could prove to be useful in these circumstances. Current evidence suggests
that low-intensity sonication of explanted prostheses is an effective means to disrupt biofilm
on the prosthetic surface to increase the sensitivity of microbiological isolation compared
to traditional sampling of synovial fluid or periprosthetic tissues [37,71,72]. Sonication
may also improve culture yield by dislodging sessile organisms on explanted prosthe-
ses [73]. Cultures of sonication fluid have demonstrated an improved sensitivity (78–97%)
in microorganism identification without compromising specificity (81–99%) [37,74–76].
In a key study by Trampuz et al., the authors found a sensitivity of 79% for sonication
fluid cultures, which was significantly greater than that of tissue cultures (61%) [37]. More
importantly, these findings persisted even in the presence of antimicrobial therapy within
14 days prior to surgery (75% vs. 45%). The superior diagnostic accuracy of sonication fluid
for microorganism identification was confirmed in a recent meta-analysis of 12 studies,
which reported a pooled sensitivity and specificity of 80% (95% CI, 0.74 to 0.84) and 95%
(95% CI, 0.90 to 0.98), respectively [77]. Despite these promising results, some authors
have suggested that the accuracy of sonication fluid cultures may vary based on the son-
ication technique used [78] as well as timing of PJI [79]. False-positive results have also
been observed and attributed to contamination during the sonication process [80]. To
overcome this limitation, most authors have recommended a diagnostic threshold of at
least five colony-forming units (CFUs) for sonication fluid cultures [37,76,77]. In view of
the overwhelming evidence demonstrating improved pathogen isolation with the use of
sonication fluid cultures relative to traditional synovial fluid or tissue cultures, sonication
of explanted prostheses for microbiological identification could be particularly useful in
the context of premature antibiotic administration wherein the risk of CN-PJI is far greater.
6. Future Solutions: Molecular Testing
The reliance on culture as the gold standard for diagnosis has led to the conundrum of
CN-PJI. Molecular techniques to detect bacterial DNA present a unique opportunity to im-
prove the accuracy of diagnosis for PJI, particularly in the setting of negative cultures [12].
Multiplex polymerase chain reaction (PCR)-based assays allow the detection of common
microorganisms and their resistance genes, improving sensitivity and reducing the time
to diagnosis compared with traditional cultures [81,82]. However, the requirement for
specific primers often results in the failure to detect atypical or less common pathogens as
well as resistance mechanisms [83]. Another molecular technique currently available is 16S
rRNA gene sequencing [81]. Unlike PCR-based assays, this method allows the detection
of a wider variety of bacterial species, prompting some authors to suggest that 16S rRNA
sequencing may have a higher sensitivity compared to bacterial cultures and PCR-based
techniques [81,84,85]. Primers used in this technique are specific for highly conserved
sequences that are found in almost all bacteria, as well as variable regions in between
them, thereby allowing the identification of a broad range of bacteria. However, major
limitations of this method include the inability to detect antimicrobial resistance genes and
polymicrobial infections, which can only be determined using high-throughput sequencing
methods rather than traditional capillary-based ones. More recently, metagenomic next
generation sequencing (mNGS) has been developed to overcome the shortcomings of
Antibiotics 2021, 10, 114 7 of 12
previous molecular tests. This high-throughput sequencing technique enables the detection
of complete bacterial genomes, including unculturable, unsuspected, and non-viable organ-
isms in the sample [86–89]. Resistance genes can also be simultaneously detected using this
technique [88]. Direct sequencing of specimens improves the diagnostic yield compared to
traditional cultures [87], as recent studies have shown that mNGS was able to detect new
organisms in 16–44% of CN-PJI cases and 4–67% of culture-positive cases [86–89].
More importantly, current evidence suggests that molecular methods for pathogen
identification are unaffected by prior antibiotic administration. Fang et al. studied 8 pa-
tients who had antibiotic treatment prior to the diagnosis of CN-PJI and found that 3 of
8 had positive rRNA-PCR and 6 of 8 had positive DNA-PCR [90]. In another study of
144 patients with PJI, Cazanave et al. reported that 69.7% of patients receiving antimi-
crobial therapy within 14 days of surgery had bacteria isolated on tissue and sonicate
fluid cultures, whereas 87.9% of patients had bacteria detected from sonicate fluid using
PCR [83]. Similarly, a higher proportion of patients on antibiotic treatment within 28 days
of surgery had a positive PCR compared to those who had a positive sonicate fluid or tissue
culture. These findings led the authors to conclude that PCR assays were less affected by
antibiotic administration compared to traditional cultures, highlighting the persistence of
microbial DNA in synovial fluid and tissue specimens following a prolonged course of
antimicrobial treatment [91]. Overall, molecular techniques show considerable promise for
diagnosing PJI in patients who inadvertently received antibiotics before the collection of
intraoperative samples, overcoming the limitations of traditional cultures. Another area
that these newer techniques can be applied to is the management of patients undergoing
two-stage exchange arthroplasty. The first stage of this procedure involves the resection
of all components, aggressive debridement, and insertion of an antibiotic-loaded cement
spacer. This is followed by an interim stage of prolonged antibiotic administration that
is guided by the susceptibility of pathogen(s) isolated from intraoperative cultures. The
second and final stage involves the removal of the spacer, repeat debridement, and implan-
tation of new prostheses. As it is often difficult to ascertain whether infection has been
eradicated following a course of four to six weeks of systemic antibiotics in the interim
stage, current practice often involves rechecking inflammatory markers such as ESR and
CRP, although this has been shown to correlate poorly with the likelihood of residual
infection at the time of reimplantation [92–94]. Alternatively, synovial fluid cultures may
be taken after an “antibiotic holiday” of two weeks to improve diagnostic yield, prior to
new prosthesis implantation. In such cases, molecular testing not only circumvents the
need for an “antibiotic holiday”, but also provides rapidly available, more sensitive diag-
nostic information that can guide clinical decisions such as the appropriateness and timing
of reimplantation [95]. The utility of molecular methods may also extend to patients on
chronic suppressive antibiotic therapy, providing a reliable method for monitoring bacterial
load as well as the development of antimicrobial resistance. However, it is important to
note that while the ability to detect bacterial DNA even after cell death from antimicrobial
therapy may seem advantageous in these situations, this is in fact a double-edged sword
as these techniques cannot differentiate between active versus eradicated infections [91],
and previous studies have demonstrated that DNA can also be isolated from non-viable
bacteria in sterile joints, especially in cases of inflammatory arthritis [96]. Consequently, the
importance of clinical correlation and adjunctive tests to support the diagnosis of PJI cannot
be further emphasized [49]. Currently, high costs and complex laboratory workflows are
the main obstacles hindering the adoption of molecular testing. As these methods become
more cost-efficient over time, their speed of detection as well as improved sensitivity in
the setting of prior antibiotic administration compared to traditional cultures will allow
clinicians to initiate targeted antimicrobial therapy at an earlier time, potentially improving
the treatment outcomes for PJI in the future.
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7. Conclusions
No single test can confirm the diagnosis of PJI, hence current diagnostic criteria are
based on both clinical as well as laboratory findings [49]. Despite recent guidelines, it is
not uncommon to encounter patients with suspected PJI who have already been prescribed
antimicrobial therapy by their primary provider. This confounds the diagnostic picture
as it interferes with the identification of the causative organism on routine cultures and
affects the accuracy of commonly used biomarkers, resulting in confusion for patients and
clinicians regarding the diagnosis as well as the inability to administer culture-directed
antimicrobials that could increase the chance of infection eradication. Based on current
literature, it is the recommendation of the authors that pre-incision prophylactic antibiotics
should not be withheld for cases of suspected PJI, but therapeutic antibiotics for the
treatment of the infected joint or any concurrent infection (e.g., urinary tract infection)
should be withheld for at least two weeks prior to the collection of intraoperative cultures
for otherwise medically-stable patients, since the early initiation of antimicrobial therapy
is unlikely to be associated with improved chances of treatment success. Exceptions to
this rule include patients in whom the causative organism has been reliably identified
prior to surgical treatment (e.g., on preoperative joint aspiration). Another exception
pertains to a patient with suspected PJI due to bacteremia from another source (e.g.,
bacterial endocarditis). Such cases should be managed according to clinical judgement—as
the need to treat the cardiac source of infection takes precedence, the patient should be
promptly started on intravenous antibiotics. However, if the patient is medically stable,
blood cultures should be taken prior to antibiotics, as this would not only guide antibiotic
selection when treating the cardiac source, but also possibly isolate the causative organism
for the infected joint. Similarly, for unstable patients in whom the infected joint has been
determined to be the source of sepsis, early collection of cultures (e.g., joint aspiration
and/or blood cultures) and initiation of antibiotic therapy should be prioritized. In the
event that a patient inadvertently received antibiotics prior to the collection of cultures,
newer molecular techniques could be used to identify the infecting organism, especially
in culture-negative cases, since their diagnostic accuracy is maintained even in patients
who receive antimicrobials prematurely. It is possible that once these highly sensitive
molecular methods gain widespread adoption, clinicians will be prompted to question the
necessity of withholding antibiotics until intraoperative sampling is performed. Until then,
it is imperative that primary care and emergency providers recognize the implications of
premature antibiotic administration as outlined in this article, as this can render an already
challenging orthopedic complication even more difficult to manage and increase morbidity
risk for the patient.
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